Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.


October 2021

Mabion Announces Commercial Manufacturing Agreement for Novavax COVID-19 Vaccine

March 2021

Mabion and Polish Development Fund signed a preliminary agreement on capital support for the production of a vaccine for COVID-19

Mabion Announces Agreement with Novavax for Large-Scale Vaccine Manufacturing Feasibility Assessment

February 2021

Mabion implements next stage of financial strategy - the Company convenes EGM to conduct public share offering and raise up to PLN 200 million to complete development and market launch of MabionCD20

January 2021

Mabion is updating its financial strategy and seeking a strategic investor and convenes a GM to pass a resolution on shares issue

September 2020

Mabion and Vaxine Enter into Memorandum of Understanding to Develop, Manufacture and Commercialize a COVID-19 Vaccine in the EU

July 2020

Mabion initiated the national and regional PCT phases of the patent application for the use of MabionCD20 in the treatment of Multiple Sclerosis (MS) patients

July 2020

Mabion received a loan from a shareholder for the repayment of credit in Santander bank

May 2020

The Management Board and the Supervisory Board of Mabion S.A. in favour of share issue to support the next phase of work in the registration of MabionCD20 in several regulated markets

November 2019

Mabion had submitted answers to the second round of questions by the European Medicines Agency (EMA) received as part of the Day 180 stage of the registration procedure for MabionCD20​

October 2018

Mabion submitted its second patent application for an innovative multiple sclerosis drug (MabionMS) and is commencing a race to win over another global market of biotech drugs

June 2018

Mabion S.A. completes marketing authorisation application for flagship drug, MabionCD20, to the European Medicines Agency (EMA)

March 2018

Mabion Announces a USD$51.0 Million Private Placement with European and US Investors

December 2017 

Mabion S.A. with a new innovative indication in the treatment of multiple sclerosis for MabionCD20

September 2017 

Positive results of the clinical trial regarding MabionCD20 in RA

March 2017

Mabion S.A. adopted a strategy plan concerning development of medicinal products

December 2016

Mabion S.A. faces international challenges and welcomes new President of the Board

November 2016

Mabion signed supply and commercialization agreement with Mylan regarding Mabion CD20 for EU

June 2016

Mabion S.A. is on track for completing the MabionCD20 clinical programme and signing a partnering contract

May 2016 

Statement of Mabion S.A.

March 2016

Biosimilar rituximab  many have started  only a few will succeed

© Mabion S.A. all rights reserved Polityka Prywatności